(Date:5/21/2013)... Illinois at Chicago College of Medicine will study gender differences ... main energy source -- and how changes in fat metabolism ... million, 4-year grant from the National Heart, Lung and Blood ... fuel for energy. These changes may play a major role ... men and women, says E. Douglas Lewandowski, director of the ...
(Date:5/21/2013)... few decades, scientists have developed many devices that can ... While generally effective, each of these treatments has drawbacks, ... study from MIT analyzes the potential usefulness of a ... and drug-releasing stents, but may pose fewer risks. With ... artery for only a brief period, during which it ...
(Date:5/21/2013)... 2013 Royal Philips Electronics (NYSE: PHG, AEX: ... portable ultrasound with Philips, industry leading Live 3D TEE, ... xMATRIX with available Live 3D TEE and ICE will ... the EuroPCR, official meeting for the European Association of ... its launch in 2012, Philips CX50 xMATRIX has been ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2(Date:5/21/2013)... -- First patients dosed with PSX1002, an ... using Prosonix, particle engineering platform Prosonix, an ... Respiratory Medicines by Design , has initiated a ... its effect on lung function and the safety of ... severe chronic obstructive pulmonary disease (COPD). The first two ...
(Date:5/21/2013)... by George Washington University Professor Tianshu Li provide ... small droplets is strongly size-dependent, an important conclusion ... formation of ice at the nanoscale is a ... has important implications for climate research and other ... supercooled water is generally initiated by a process ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, innovative ... Genzyme, a Sanofi company and leading biotech company, recently ... a multi-use facility in the United States. With Door ... this latest order underscores the satisfaction and success the ... device improving doorway access control. , “We recommend ...
(Date:5/21/2013)... , May 21, 2013 MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM. The presentation will describe ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3